Trends and Global Projections for the Liquid Biopsy Market by 2035: Investors Contribute Approximately USD 7.3 Billion Across More Than 125 Funding Events in the Last Nine Years

Market Growth: The liquid biopsy market is expected to grow from USD 6.09 billion to USD 29.8 billion by 2035, with a CAGR of 15.53%, driven by demand for non-invasive cancer diagnostics and advancements in technology.

Key Segments: Early cancer diagnosis, particularly for breast cancer, dominates the market, with circulating tumor DNA as the preferred biomarker and blood samples being the most common type used.

Regional Insights: North America is projected to hold the largest share of the liquid biopsy market, followed closely by Asia-Pacific, as investments and research efforts increase in these regions.

Industry Dynamics: Over 180 liquid biopsy products are currently available, with significant partnerships and investments totaling around USD 7.3 billion in the past nine years, indicating strong interest and growth potential in this sector.